Comparison of Cryoballoon Ablation for Atrial Fibrillation Guided by Real-Time Three-Dimensional Transesophageal Echocardiography vs. Contrast Agent Injection
Atrial fibrillation (AF) is the most prevalent arrhythmia, with triggers often originating from the pulmonary veins (PVs). Pulmonary vein isolation (PVI) targeting the left atrial (LA)-PV junction is the standard ablation strategy for drug-refractory AF. Cryoballoon ablation, a relatively novel technology, has proven effective for PVI in AF. This technique uses liquid nitrous oxide delivered under pressure in a balloon to freeze surrounding tissue, achieving electrical isolation of the PVs from the LA. However, cryoballoon ablation typically relies on repetitive contrast agent injection to confirm PV occlusion, which can lead to prolonged radiation exposure and potential contrast-induced kidney injury. This study compares the efficacy and safety of cryoballoon ablation guided by real-time three-dimensional transesophageal echocardiography (TEE) versus traditional contrast agent injection for PV occlusion.
Background and Rationale
Cryoballoon ablation has emerged as a viable alternative to radiofrequency (RF) ablation for PVI in AF. The second-generation cryoballoon, in particular, has demonstrated high acute procedural success rates with low complication rates. However, the procedure traditionally requires contrast agent injection to confirm PV occlusion, which exposes patients and operators to increased radiation and contrast load. TEE offers a potential solution by providing real-time imaging to guide balloon positioning and confirm PV occlusion without the need for contrast. This study aims to evaluate the feasibility, safety, and efficacy of TEE-guided cryoballoon ablation compared to the conventional contrast-based approach.
Methods
Study Design and Patient Population
The study enrolled 80 patients with drug-refractory symptomatic paroxysmal AF (PAF) who were referred for their first catheter ablation. Patients were randomly divided into two groups: 40 underwent cryoballoon ablation with TEE guidance (TEE group), and 40 underwent ablation without TEE (non-TEE group). All patients were free of congenital heart disease, thyroid dysfunction, moderate-to-severe valvular heart disease, or prior cardiac surgery. Baseline characteristics, including age, gender, left atrial size, left ventricular ejection fraction (LVEF), and CHA2DS2-VASc scores, were similar between the two groups.
Cryoballoon Ablation Procedure
All patients underwent a cardiac computed tomography scan to reconstruct three-dimensional (3D) anatomical models of the LA and PVs. The ablation procedure was performed under general anesthesia and endotracheal intubation using the second-generation cryoballoon (Arctic Front Advance, Medtronic). A 28-mm balloon was used for all PVs. In the non-TEE group, PV occlusion was confirmed using contrast agent injection under fluoroscopic guidance. In the TEE group, PV occlusion was guided by real-time 3D TEE imaging, with contrast agent injection used only when TEE failed to confirm occlusion.
TEE-Guided Ablation Protocol
The TEE probe was positioned in the mid-esophagus, and PVs were displayed in a longitudinal plane. The balloon was adjusted based on 3D TEE images to achieve PV occlusion. If occlusion was not achieved, the balloon was repositioned until no PV flow was visible on the echocardiographic image. Fluoroscopy and contrast agent injection were used as a last resort in the TEE group. The esophagus was assessed in 3D geometry, and the TEE probe was moved contralaterally to reduce the risk of esophageal injury during ablation of the left PVs.
Post-Procedural Management and Follow-Up
After the procedure, patients received anticoagulation therapy for at least three months. Follow-up visits were scheduled every two months, during which a 12-lead electrocardiography (ECG) and 24-hour Holter monitoring were performed. Recurrence of atrial tachyarrhythmia lasting longer than 30 seconds after the three-month blanking period was considered a procedural failure.
Results
Baseline Characteristics
The study included 80 patients (mean age 59.2 ± 7.8 years, 51.3% male). The mean LVEF was 57.9 ± 1.4%, and the mean left atrial size was 37.3 ± 3.6 mm. The time course of AF was 2.9 ± 2.6 years. No significant differences were observed in baseline characteristics between the TEE and non-TEE groups.
Procedural Data
All patients successfully completed the procedure without acute complications. Acute PVI was achieved in all 320 PVs (160 in each group). There were no significant differences in procedure time or ablation time for each PV between the two groups. However, the TEE group had significantly shorter fluoroscopy time (6.7 ± 4.2 minutes vs. 17.9 ± 5.9 minutes, P < 0.05) and lower contrast agent load (3.0 ± 5.1 mL vs. 18.1 ± 3.4 mL, P < 0.05) compared to the non-TEE group.
TEE-Guided Occlusion
In the TEE group, 160 PVs were visualized, and 11 required fluoroscopy and contrast agent injection for occlusion. The esophagus was located near the left PVs in 70% of patients, midline in 17.5%, and near the right PVs in 12.5%. The TEE probe was moved contralaterally in 35 patients to reduce the risk of esophageal injury during ablation of the left PVs, with a mean movement distance of 2.1 ± 0.2 cm for the left superior PV and 2.2 ± 0.2 cm for the left inferior PV.
Follow-Up Outcomes
At a mean follow-up of 13.0 ± 3.3 months, the overall success rate was 78.8%, with no significant difference between the TEE and non-TEE groups (77.5% vs. 80.0%, P = 0.88). No symptoms of pulmonary vein stenosis or atrio-esophageal fistula were reported during follow-up.
Discussion
Major Findings
This study demonstrates that cryoballoon ablation guided by real-time 3D TEE is both feasible and effective for PV occlusion in AF. The use of TEE significantly reduces fluoroscopy time and contrast agent load compared to traditional contrast-based methods. Acute PVI was achieved in all patients, and the success rates were comparable between the TEE and non-TEE groups.
Radiation Exposure and Contrast Load
Radiation exposure is a significant concern for both patients and operators during cryoballoon ablation. The TEE-guided approach reduced fluoroscopy time from 17.9 ± 5.9 minutes to 6.7 ± 4.2 minutes, which is a substantial reduction. Similarly, the contrast agent load was significantly lower in the TEE group (3.0 ± 5.1 mL vs. 18.1 ± 3.4 mL). These reductions are particularly beneficial for patients with impaired renal function or those sensitive to contrast agents.
Advantages of TEE Guidance
TEE provides several advantages over traditional contrast-based methods. It allows for real-time monitoring of balloon positioning and PV occlusion, reducing the need for fluoroscopy and contrast agent injection. Additionally, TEE can be used to rule out intracardiac thrombi and assess the spatial relationship between the esophagus and PVs, reducing the risk of esophageal injury. The switch from two-dimensional to 3D imaging further enhances the precision of balloon positioning.
Comparison with Intracardiac Echocardiography (ICE)
While ICE is another imaging modality used in cryoballoon ablation, it requires the insertion of a large-bore venous sheath and is associated with a higher risk of complications such as femoral deep venous thrombosis. TEE probes are reusable and more cost-effective, making them a practical alternative to ICE.
Limitations
The study has several limitations, including its relatively small sample size and the lack of blinding for operators. The mechanism of atrial tachyarrhythmia recurrence was not analyzed, and temperature monitoring in the esophagus was not performed. Larger studies are needed to confirm the benefits of TEE-guided cryoballoon ablation and its impact on reducing esophageal injury.
Conclusion
Cryoballoon ablation guided by real-time 3D TEE is a safe and effective alternative to traditional contrast-based methods for PV occlusion in AF. The use of TEE significantly reduces fluoroscopy time and contrast agent load, offering benefits for both patients and operators. The technique also provides additional safety measures by reducing the risk of esophageal injury. Further studies with larger patient populations are warranted to validate these findings and explore the long-term outcomes of TEE-guided cryoballoon ablation.
doi.org/10.1097/CM9.0000000000000076
Was this helpful?
0 / 0